Results 191 to 200 of about 126,909 (281)

The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review. [PDF]

Heart Fail Rev
Othman L, Koskina L, Huerta N, Rao SJ.
europepmc   +1 more source

Disruption of ATP Synthase Spatiotemporal Organization, Ca2+ Dynamics, and Contractile Function in Senescent Cardiomyocytes

Aging Cell, Volume 25, Issue 2, February 2026.
Enhanced ATP hydrolysis, ΔΨm flickering, and destabilized ATP synthase dimers collectively reduce ATP availability in senescent cardiomyocytes. This energy deficit is associated with disrupted Ca2⁺ dynamics and contractility. ABSTRACT Heart disease is the leading cause of death in the elderly population.
Silke Morris, Nico Marx, Gonzalo Barrientos, Isidora Molina‐Riquelme, Frank Schmelter, Hugo E. Verdejo, Stefan Peischard, Guiscard Seebohm, Verónica Eisner, Karin B. Busch   +9 more
wiley   +1 more source

The Baraitser–Winter Cerebrofrontofacial Syndrome Recurrent R196H Variant in Cytoplasmic β‐Actin Impairs Its Cellular Polymerization and Stability

The FASEB Journal, Volume 40, Issue 1, 15 January 2026.
BWCFF, a severe disease with neurological symptoms, is caused by mutations in the cytoskeletal actin genes. Patient‐derived fibroblasts carrying the R196H β‐actin mutation were compared to wild type cells. The mutant cells displayed slower proliferation and migration and a lower F‐actin content, which correlated with reduced cell stiffness ...
Éva Gráczer, Elena Battirossi, Tamás Bozó, Áron Gellért Altorjay, Katalin Pászty, Laura Harsányi, Johannes N. Greve, Irene Pertici, Massimo Reconditi, Nataliya Di Donato, Miklós Kellermayer, Pasquale Bianco, Andrea Varga   +12 more
wiley   +1 more source

Emerging Pharmacological and Invasive Therapies for Hypertrophic Cardiomyopathy with Obstructive Physiology. [PDF]

Card Fail Rev
Li-Wen Chu E, Seung Kim D, Masri A.
europepmc   +1 more source

Non-muscle myosin II is a promising therapeutic target. [PDF]

Trends Pharmacol Sci
Miller CA, Quinones-Hinojosa A, Rosenfeld SS.   +2 more
europepmc   +1 more source

Current and emerging medical and surgical therapy in hypertrophic cardiomyopathy. [PDF]

J Cardiovasc Imaging
Kim KA, Jung MH.
europepmc   +1 more source

Cellular and Molecular Mechanisms of Heart Failure and Sudden Cardiac Death in Hypertrophic Cardiomyopathy and Methods Used for Their Pathogenetic Correction. [PDF]

Biomedicines
Kakturskiy L, Belov Y, Mikhaleva L, Lysenko A, Gioeva Z, Tikhonova N, Gutyrchik N.   +6 more
europepmc   +1 more source

Pediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future. [PDF]

Rev Cardiovasc Med
Das BB.
europepmc   +1 more source

Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Cardiovasc Dev Dis
Saleh D, Kim EY, Hussain K, Samhan A, Shi M, Meng Z, Schormann E, Bindra P, Cheema B, Fullenkamp DE, Baldridge AS, Puthumana JJ, Rigolin VH, Cremer PC, Flaherty JD, Choudhury L.   +15 more
europepmc   +1 more source

Mavacamten facilitates myosin head ON-to-OFF transitions and shortens thin filament length in relaxed mouse skeletal muscle. [PDF]

Physiol Rep
Kuehn MN, Engels NM, Nissen DL, Freundt JK, Ma W, Harris SP, Irving TC, Linke WA, Hessel AL.   +8 more
europepmc   +1 more source